来源:药渡撰文:Pharmadeep编辑:维他命近日,全球生物医药领域关于ADC(抗体药物偶联物)的重磅交易接连不断。1月14日,国内ADC外包服务龙头药明合联宣布收购东曜药业,旨在整合打造全球领先的一站式生物偶联药物CRDMO平台(估值30.91亿港元!药明合联收购东曜药业);1月9日,宜联生物B7H3 ADC授权罗氏,获得5.7亿美元首付款及近期里程碑付款(B7-H3,下一款“爆款ADC”的...
Source Link来源:药渡撰文:Pharmadeep编辑:维他命近日,全球生物医药领域关于ADC(抗体药物偶联物)的重磅交易接连不断。1月14日,国内ADC外包服务龙头药明合联宣布收购东曜药业,旨在整合打造全球领先的一站式生物偶联药物CRDMO平台(估值30.91亿港元!药明合联收购东曜药业);1月9日,宜联生物B7H3 ADC授权罗氏,获得5.7亿美元首付款及近期里程碑付款(B7-H3,下一款“爆款ADC”的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.